Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02859324 · ClinicalTrials.gov registry record · Phase 1
A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT02859324 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 21 participants.
The verdict
NCT02859324, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
CC-122-HCC-002 is a Phase 1/2 dose escalation and expansion clinical study of CC-122 in combination with nivolumab in subjects with unresectable hepatocellular carcinoma (HCC) who have progressed after or were intolerant to no more than 2 previous systemic therapies for unresectable HCC, or are naïve to systemic therapy.
Interventions
- DRUG Nivolumab
- DRUG CC-122
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-09-20 |
| Est. Completion | 2020-03-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02859324
The ClinicalTrials.gov registry entry for NCT02859324 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02859324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02859324 about?
NCT02859324 is a clinical study titled "A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)". CC-122-HCC-002 is a Phase 1/2 dose escalation and expansion clinical study of CC-122 in combination with nivolumab in subjects with unresectable hepatocellular carcinoma (HCC) who have progressed after or were intolerant to no more than 2 previous systemic therapies for unresectable HCC, or are naïv...
What is the current status of trial NCT02859324?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2016-09-20. Estimated completion is 2020-03-27.
What interventions are being tested in trial NCT02859324?
The interventions under investigation include: Nivolumab (DRUG), CC-122 (DRUG).
Who is sponsoring clinical trial NCT02859324?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.